Pancreatic cancer-improved care achievable

Figure 1 Treatment algorithm for pancreatic tumors including only patients with borderline resectable lesions in randomized controlled trial (A), alternative model, including primary resectable and borderline resectable tumors in randomized controlled trial, comparing outcome of upfront surgery and neoadjuvant chemotherapy (B).

Figure 2 ESAS and pancreatic cancer disease impact form in a patient with serum bilirubin 550 μmol/L, illustrating that only the disease specific instrument enables report on the patient’s most severe problem.